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Fixed tobramycin (mg/kg) dosing is often inappropriate in patients with cystic fibrosis (CF), as pharmacokinetics are highly
variable. The area under the concentration-time curve (AUC) is an exposure metric suited to monitoring in this population.
Bayesian strategies to estimate AUC have been available for over 20 years but are not standard practice in the clinical setting. To
assess their suitability for use in clinical practice, three AUC estimationmethods using limited sampling were compared to mea-
sured true exposure by using intensive sampling tobramycin data. Adults prescribed once daily intravenous tobramycin had
eight concentrations taken over 24 h. An estimate of true exposure within one dosing interval was calculated using the trapezoi-
dal method and compared to three alternate estimates determined using (i) a two-sample log-linear regression (LLR) method
(local hospital practice); (ii) a Bayesian estimate using one concentration (AUC1); and (iii) a Bayesian estimate using two concen-
trations (AUC2). Eachmethod was evaluated against the true measured exposure by a Bland-Altman analysis. Twelve patients
with a median (range) age and weight of 25 (18 to 36) years and 66.5 (51 to 76) kg, respectively, were recruited. There was good
agreement between the true exposure and the three alternate estimates of AUC, with a mean AUC bias of<10 mg/liter · h in each
case, i.e.,8.2 (LLR), 3.8 (AUC1), and 1.0 (AUC2). Bayesian analysis-based and LLR estimationmethods of tobramycin AUC are
equivalent to true exposure estimation. All three methods may be suitable for use in the clinical setting; however, a one-sample
Bayesian methodmay be most useful in ambulatory patients for which coordinating blood samples is difficult. Suitably pow-
ered, randomized clinical trials are required to assess patient outcomes.
Approximately 70,000 patients worldwide have cystic fibrosis(CF) (1), and it is the most common life-threatening genetic
disorder. The mortality and morbidity in CF patients are often
attributed to Pseudomonas aeruginosa-induced pulmonary exac-
erbations for which intravenous (i.v.) and inhaled antibiotics are
used to prevent and treat recurrence (2, 3).
Intravenous tobramycin, an aminoglycoside antibiotic, is a
mainstay in the treatment of Pseudomonas infection in patients
with CF (1, 4). Tobramycin is most commonly administered as a
daily i.v. injection in doses ranging from 7 to 15 mg/kg of body
weight per day (1, 4, 5). The bactericidal actions of tobramycin are
directly linked to drug exposure; however, dosing is complicated,
as exposure must be maintained within a narrow therapeutic
range (TR) (4–6). Exposures above the TR increase the risk of
nephrotoxicity (1) and ototoxicity, of which the latter can be irre-
versible (1, 7). Exposures below the TR can lead to therapeutic
failure, increased antibiotic resistance, and poor patient outcomes
(2, 3). To help ensure optimal therapy, a therapeutic exposure
must be achieved as quickly as possible (8, 9), preferably after the
first dose of a treatment course, which can last up to 14 days (10).
Unfortunately, in CF patients, tobramycin has high between-
subject variability in its pharmacokinetic (PK) parameters, such as
clearance (CL) and volume of distribution (V) (11, 12). Serum
tobramycin concentrations are used to estimate exposure after a
given dose, often by the area under the concentration-time curve
(AUC). There is consensus that therapeutic drug monitoring
(TDM) should be conducted as part of standard practice (1, 4). A
target used to assess efficacy for aminoglycosides is the AUC/MIC
ratio (13) with an acceptable target range of 70 to 100 mg/liter · h
(14, 15), assuming an MIC of 1.
Locally, clinical pharmacists perform tobramycin monitoring
and estimate an AUC for dose adjustment by using two blood
concentrations and the log-linear regression (LLR)method.How-
ever, from a practical point of view, the collection of two blood
samples is difficult and time-consuming to coordinate, especially
in an outpatient setting, where patients are administered the an-
tibiotic in hospital and are able to leave between blood tests. How-
ever, they often fail to present for their second blood sample at the
correct time. Bayesian analysis-based software can be used to es-
timate AUC (16) and has the potential to be more accurate than
conventional methods and to allow the collection of samples at
unrestricted, patient-preferred times (17).
Bayesian analysis-based programs use embedded population
PK models (16–18). The user can input known patient demo-
graphics (age, sex, weight, renal function) to allow the estimation
of a concentration-time curve based on the population model. As
tobramycin concentration data are obtained, these, along with
dosing details, can be input to estimate patient-specific PKparam-
eters, which can be used to estimate an exposuremetric such as an
AUC, maximum concentration (Cmax), or minimum concentra-
tion (Cmin). Given these individualized values, dosing and moni-
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toring strategies can be personalized in a dynamic way. As subse-
quent patient data and tobramycin concentrations are collected,
further individualization can occur, potentially with the use of
only one concentration (17, 19, 20).
The aim of this study was to evaluate three AUC estimation
methods by comparison to true measured exposure, calculated
using intensive sampling data, in adult CF patients to assess their
suitability for use in clinical practice.
MATERIALS AND METHODS
Figure 1 shows the flow chart for recruitment and data analysis. Data
were collected from adult CF patients admitted as inpatients to the
Mater Health Service (MHS) RespiratoryUnit, Brisbane, Australia, over a
3-month period. On admission, tobramycin was administered as a once
daily infusion over 30 min, per hospital protocol. This dose was either 10
mg/kg, based on total body weight, or a dose equivalent to the last dose
that was prescribed during the previous admission.
Patients were treated using local dosing andmonitoringmethods until
a suitable day was organized for the patient to participate in a rich sam-
pling protocol. This occurred only after the patient had attained a thera-
peutic AUC as required by the treating physician, commonly between 70
and 100 mg/liter · h. At the MHS, patients do not have to remain in
hospital while on their 10- to 14-day course of i.v. tobramycin and return
only for daily dose administration or blood sampling. Local hospital prac-
tice is to collect two serum tobramycin concentrations from each patient
within one dosing interval: the first is collected 1 to 1.5 h after the com-
mencement of the infusion, and the second is collected at 8 to 12 h after
commencement of the infusion. An AUC from 0 to 24 h (AUC0–24) is
estimated using an LLR method (21) embedded in a Microsoft Excel-
based program, and the dose is adjusted to the TR if necessary.
For this study, a rich sampling strategy was implemented following a
morning dose, with eight serum drug concentrations taken over the 24-h
dosing interval, i.e., a predose sample and an additional seven samples at
50, 70, 100, 160, 280, 520, and 640 min after the start of infusion (30-min
duration) to enable calculation of true tobramycin exposure (AUC0–24)
after this dose.
Comparison of AUC estimation methods. AUCs were estimated us-
ing four methods (Fig. 1): calculation of a true exposure by use of the
traditional trapezoidal method (linear-up log-down) (22), a Bayesian
method with either one serum drug concentration (AUC1) or two serum
drug concentrations (AUC2), and the local hospital method utilizing the
LLR method (21). It has been postulated that Bayesian software does not
require a minimum number of concentrations to calculate an AUC (20);
therefore, an AUC was calculated using one concentration, taken at 520
min postdose. In addition, a two-sample AUC was calculated using con-
centrations taken at 100 and 520 min postdose. The times were chosen as
they match those used at the hospital to estimate an LLR AUC (local
method). Previous reports have demonstrated that no additional reliabil-
ity in the estimation of concentrations is gained by sampling beyond 6 h
postdose (11, 19); however, the concentration at 520minwould not com-
promise the estimation of the AUC and matches local practice. All AUC
calculations used the sampling data from the same dosing interval, and no
Bayesian optimization using previous patient data occurred before the
study day for this study.
Demographic datawere summarizedusing standard statistics. Bland-Alt-
man difference plots were used to compare the AUC of each method to the
true AUC (trapezoidal). The mean difference (bias) and upper and lower
limits of agreement (95% confidence interval [CI]) were calculated and plot-
ted. The percentage change in bias was reported. Statistical difference was
considered at a P value of0.05 (Tukey’s test).
Ethics approval was obtained from the MHS Human Research Ethics
Committee. The software TDMx (23) was used for the Bayesian analyses,
embedded with the population PK model described by Hennig et al. (6).
All statistical and graphical analyses were performed using the software
Prism (version 7).
RESULTS
Data were collected from 12 patients with CF. Table 1 shows the
demographics of the population. The medians (ranges) for age,
weight, and tobramycin dose of the population were 25 (18 to 36)
years, 66.5 (51 to 76) kg, and 400 (320 to 640) mg, respectively.
FIG 1 Study flow chart. AUC, area under the concentration-time curve (mg/liter · h); CF, cystic fibrosis.
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The estimated AUC values using the four methods for each of the
12 patients are shown in Table 2.
The Bland-Altman plots are shown in Fig. 2a to c, and a sum-
mary of the bias, percent change in bias, and limits of agreement
(95% CIs) between the true exposure and the results of the three
estimation methods is shown in Table 3. There was no significant
difference in bias relative to the mean of the true measured expo-
sure for any of the three AUC methods, with the mean AUC bias
less than 10 mg/liter · h in each case. The AUC2 method was the
least biased. There was a wide range between the lower and upper
limits of agreement for all methods; however, the AUC2 method,
with a range of 24.9mg/liter · h, was themost preferred (change in
bias, 1.03%).
When the two Bayesian methods are compared, Fig. 2 shows
that the AUC2 method performs better than AUC1 method when
patient results are farther away from the population average. This
is expected, as the Bayesian software will use the prior model
rather than the actual data to optimize model parameters. Gener-
ally, these results indicate that when estimating a tobramycin
AUC, it would be reasonable to use all three methods.
DISCUSSION
Pseudomonas aeruginosa is the most common bacterium to infect
the lungs of individuals with CF (1), and tobramycin, given i.v.
once daily, is a first-line antibiotic to treat and prevent infection
(1, 4, 5, 24). However, the TR for tobramycin is often difficult to
achieve with standard dosing and monitoring methods (11, 17,
25), which is hazardous, as toxicity is linked to severe adverse
effects such as irreversible nephrotoxicity and ototoxicity (7, 26,
27). CF patients generally require large doses of tobramycin, often
for extended periods of time (10 to 14 days), which can increase
the risk of toxicities (7, 26, 27). In addition, patients may attend
TABLE 1 Patient demographics
Demographic No. or median (range)
Age, yr 25 (18–36)
Weight, kg 66.5 (51–76)
Height, cm 170 (154–185)
Gender
Male 7
Female 5
Serum creatinine, mol/liter 73 (55–92)
Dose at study day, mg 400 (320–640)
Dose, mg/kg 6.3 (5.2–8.4)
Day of therapy for sampling 6 (4–7)
TABLE 2 Tobramycin AUC by methoda
Patient
AUC (mg/liter · h) by:
Trapezoidal
method
LLR method,
2 samples
Bayesian method,
1 sample (AUC1)
Bayesian method,
2 samples (AUC2)
1 88.9 104.6 86.8 92.9
2 94.9 100.3 107.6 105.3
3 71.9 92.4 76.1 73.3
4 79.3 97.1 68.7 70.5
5 79.8 74.9 69.0 78.6
6 81.5 88.1 74.6 78.4
7 71.9 97.6 65.2 70.0
8 102.4 111.2 87.9 99.4
9 102.8 92.4 87.8 91.4
10 62.7 59.4 56.1 55.3
11 77.6 87.1 77.6 80.3
12 51.1 57.8 61.4 57.1
a AUC, area under the concentration-time curve; AUC1, sampling at 520 min postdose;
AUC2, sampling at 100 and 520 min; LLR, log-linear regression; trapezoidal method,
true exposure calculated using the linear-up log-down trapezoidal method.
FIG 2 Bland-Altman plots with mean difference (solid lines) and upper and
lower limits of agreement (95% confidence intervals) (dashed lines). (a) Trap-
ezoidal method versus LLR method; (b) trapezoidal method versus AUC1
method; (c) trapezoidal method versus AUC2 method. AUC, area under the
concentration-time curve (mg/liter · h); trap, calculation of the true exposure
(AUC) via the trapezoidal method; LLR, log-linear regression method. The
Bayesian method used one serum concentration (AUC1) or two serum con-
centrations (AUC2).
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hospital at regular intervals, during which i.v. tobramycin may be
administered to reduce the Pseudomonas inoculum and prevent
further acute exacerbations. There is ongoing concern about tox-
icity due to the repetitive nature of tobramycin exposure (4).
Bayesianmethods have been used in the TDMof drugs for over
20 years; however, they are still not a commonly used strategy in
the clinical setting, in particular in Australia and the United King-
dom (16, 28, 29). This may be attributed to a lack of one or more
of the following: the availability of licensed software, the availabil-
ity of skilled users, an understanding of Bayesian principles, and
validation in a clinical setting. Certainly, local clinicians have ex-
pressed the lack of validation in a clinical setting. Bayesian moni-
toringmethods have gained importance in the CF population due
to the narrow TR and the sufficient unexplained interpatient vari-
ability and low intrapatient variability in PK parameters (and re-
sponse) (11). In addition, tobramycin distribution may be better
described using two-compartmental PK (30). As such, fixed-dos-
ing, traditional nomograms (31) and PK software that use non-
compartmental models should be used with caution if only one or
two serum concentrations are available (17).
As the use of the AUC method for monitoring tobramycin
exposure is growing (4, 14), a number of dose prediction software
programs are available (16–18, 31). However, they can be unpal-
atable, as they often lack networking capabilities, use databases
that are not compatible with hospitals’ information technology
(IT) systems, or have little readily accessible IT support. The new
Bayesian method-based software used in this analysis can be
accessed from the Internet (http://www.tdmx.eu/Resources/) free
of charge.
Our study has shown that the Bayesian estimation of AUC is
similar to the local method using LLR with two concentrations.
Other studies have shown the superiority of Bayesian dosing and
monitoring methods over traditional methods for aminoglyco-
side exposure estimation (17, 18, 25). Recently, Hennig et al. (17),
compared Bayesian estimation to LLR and nomogram methods
for the dosage adjustment of tobramycin in children with CF. The
LLRmethod and Bayesian forecasting methods showed negligible
bias but imprecision of 20% in predicting subsequent observed
concentrations. The Bayesian methods were recommended as the
first line for dose adjustment. However, this study had nomeasure
of total exposure for comparison. Our study is the first in which
true tobramycin exposure was used as a comparator and allows a
robust evaluation of Bayesian methods.
Learning about the patient is the strength of a Bayesian ap-
proach. The clinician gains a better knowledge of each patient’s
true PK response; i.e., the clinician “learns” about the patient, the
true benefit of a Bayesian system. This is in contrast to the local
LLR method, which assumes a one-compartment PK model for
tobramycin. As no prior PK parameters are included, two blood
concentrations are required at every monitoring occasion.
The practical difficulties when using LLR for tobramycin TDM
is that patients and phlebotomy staff have to present on two occa-
sions for blood collection,which is often difficult to coordinate. As
a consequence, pathology results are seldom available during
work hours, which is problematic formedical and pharmacy staff.
Dose individualization may be compromised, which delays the
time to TR and thus increases the risk of unwanted patient out-
comes. In addition, regular dose adjustments result in further
blood sampling, which is costly to the hospital and cumbersome
for staff and patients. A one-concentration AUC means that pa-
tients are not required to remain as inpatients and adds to the
argument of the cost-effectiveness of a coordinated TDM ap-
proach (32).
Finally, as intrapatient variability is low in CF patients (33), an
accurate estimation of a patient’s PK parameters after one hospital
stay aids dose selection in the future. Currently, a 10-mg/kg fixed
dose is often administered to patients on admission. Our results
suggest that an ideal method for monitoring would be to use a
two-sample method for the first dosing interval, which allows op-
timization of the patient’s PK parameters, and then a one-sample
method thereafter. A prospective evaluation of this hypothesis is
required.
There are limitations to our study, notably with the generaliz-
ability of results. We had a small sample size (n 12), limited by
funding and time; however, this prospective study provides im-
portant data to design adequately powered investigations. A large
comparative study may allow the investigation of relevant patient
outcomes, such as disease progression, lung function, time to ex-
acerbation, and drug toxicity (nephrotoxicity or ototoxicity). Un-
fortunately, few data exist demonstrating the benefits of a Bayes-
ian dosing andmonitoring approach using tobramycin for clinical
outcomes, and we cannotmake clinical assumptions using a small
sample. Finally, the population PK model embedded in the soft-
ware was developed from patients with CF and therefore should
be used only in this population.
Conclusion.AnAUC approach for the dosing andmonitoring
of tobramycin is advocated practice in CF populations. Both
Bayesian and LLR estimation methods of tobramycin AUC are
equivalent to a true exposure estimate. However, Bayesian estima-
tion using a single serum concentration may be a more practical
method. Suitably powered, randomized clinical trials are required
to assess patient outcomes.
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